ME15 Current molecular treatment landscape of advanced colorectal cancer based on COLOMATE platform and collaboration with SCRUM-Japan GOZILA

Abstract

Circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) assays offer meaningful advantages over tissue-based analyses given their improved representation of the totality of the cancer including real time and repeated sampling. Additional advantages include their low invasiveness and rapid turnaround time. Given the low incidence of most target gene alterations in colorectal cancer, large collaborative screening platforms are critically needed to develop rational genome-based molecularly targeted clinical trials.